Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news
High drug prices? Some pharma firms will send you a check
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. (Source: CNN.com - Health)
Source: CNN.com - Health - December 28, 2018 Category: Consumer Health News Source Type: news
The Little-Known Way Pharma Companies Hook People On Their Costly Drugs
Kip Burgess was relieved last year when pharmaceutical giant Amgen overnighted him a $2,976 check to help pay for his go-to arthritis drug, Enbrel. The 36-year-old psychologist had run into an increasingly common problem: The copay coupon sent by Amgen couldn’t cover the drug’s more than $4,000 monthly price.
“Nothing in the world gives me more anxiety than just getting my medication,” Burgess said. “There’s nothing you can do but beg.”
Panicked, Burgess had called Amgen and pleaded for help. The drugmaker sent him the check after he provided a credit card statement and an explanat...
Source: TIME: Health - December 12, 2018 Category: Consumer Health News Authors: Sarah Jane Tribble / Kaiser Health News Tags: Uncategorized Drugs Source Type: news
Questions Remain About Etanercept to Biosimilar Switch Questions Remain About Etanercept to Biosimilar Switch
Nationwide registry data from patients with inflammatory arthritis showed many had similar outcomes with biosimilar, but the study did not show conclusively that the two drugs are interchangeable.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 21, 2018 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Medical News Today: Differences between Enbrel and Humira
Enbrel and Humira are medications that doctors prescribe to treat rheumatoid arthritis and other conditions. Both help lower inflammation in the joints and are similar, regarding their available forms, storage, and costs. Learn more about Enbrel and Humira, and which might be the most appropriate, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 13, 2018 Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL ® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Results From Head-To-Head Phase 3 SEAM-PsA Study Assessing ENBREL and Methotrexate Regimens in Patients With Psoriatic Arthritis Presented at 2018 ACR/ARHP Annual Meeting
Additional Phase 3b Results Show Modified ENBREL Formulation Associated With Significantly Lower Mean Injection Site Pain Versus Prior Formulation
Data Presentations Result of Continued Dedication to Evaluate Optimal Use of ENBREL
THOUSAND OAKS, Calif., Oct. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that positive results from the Phase 3 SEAM-PsA study comparing the efficacy of Enbrel® (etanercept) monotherapy and ENBREL plus ...
Source: Amgen News Release - October 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Bringing Hollywood to Medtech
Typically, the tutorials for medical devices aren’t extremely flashy. The videos convey a simple message and get straight to the point. However, one company is bringing high quality production levels to the medtech industry. Spotburner is a specialist in producing videos for healthcare companies.
“I have a television studio and I have been producing commercials for about 20 years,†Bob Bekian, CEO of Spotburner told MD+DI. “Typically, these sort of productions (medical device videos) have been a must-do, but they haven’t been able to ...
Source: MDDI - July 27, 2018 Category: Medical Devices Authors: Omar Ford Tags: Regulatory and Compliance Source Type: news
Biocon puts arthritis drug on backburner
Biocon and Mylan have been working for a decade on a biosimilar version of the drug, originally sold by Amgen under brand name Enbrel. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 11, 2018 Category: Pharmaceuticals Source Type: news
Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will p... Biopharmaceuticals, Generics Mylan, Lupin, biosimilar, Enbrel, etanercept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news
Lupin-Mylan team up for biosimilar Etanercept
Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with an equal share in net profits of the product. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 28, 2018 Category: Pharmaceuticals Source Type: news
Lupin, Nichi-Iko tie up for commercialization of biosimilar Etanercept in Japan
Mumbai based Lupin pharma and Japan's Nichi-Iko have tied up for the distribution, promotion and sale of Lupin ’s recently-filed biosimilar Etanercept in Japan. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2018 Category: Pharmaceuticals Source Type: news
Novartis touts effectiveness, safety of autoimmune drug copies
ZURICH (Reuters) - Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson& Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. (Source: Reuters: Health)
Source: Reuters: Health - June 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)
Title: Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)Category: Doctor's& Expert's views on SymptomsCreated: 11/20/2003 12:00:00 AMLast Editorial Review: 6/13/2018 2:55:08 PM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - June 13, 2018 Category: Dermatology Source Type: news
Low Doses of Etanercept to Maintain Remission in PsA Low Doses of Etanercept to Maintain Remission in PsA
Find out how psoriatic arthritis patients who have achieved sustained remission with etanercept may benefit from a dosing interval increase.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 23, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Finding Good Candidates for Risk-Sharing Arrangements
Continued from Part I that discusses the tools device manufacturers can use to manage risk
How to find good candidates?
Not all devices are created equal. But how can device manufacturers identify the low-hanging fruit for a risk-sharing arrangement? Needless to say, the more characteristics a product has that are associated with successful risk-sharing arrangements, the more such an arrangement is likely to succeed.
To illustrate, in Exhibit 1, we chart a select number of risk-sharing arrangements established since 2015 along two key dimensions: product effectiveness and time needed to observe expected outcomes. The findi...
Source: MDDI - April 3, 2018 Category: Medical Devices Authors: Harry Liu and Christine Chen Tags: Contract Manufacturing Design Source Type: news
